Moderna Shares Surged 663 Percent Through 2026
Investors are weighing the company's re-entry into the Nasdaq-100 index against volatile trial news for a new cancer vaccine.
Updated on Oct. 10, 2026 in Stock Markets
Live Poll
Is now a good time to invest in companies experiencing major stock price volatility?
Moderna shares climbed 663 percent in 2026, closing at $225 on October 9 as the company rejoined the Nasdaq-100 index. The performance follows a year of organizational changes, including the reduction of over 800 staff positions in 2025.
Why it matters
The company's inclusion in the Nasdaq-100 index forces more than 200 index-tracking funds holding over $800 billion in assets to purchase shares, significantly influencing demand. This institutional buying comes alongside market optimism regarding positive results from a final-stage cancer vaccine trial conducted with Merck.
Moderna stock rose 663 percent year-to-date with a market capitalization of approximately $89.8 billion. This is notable compared to the S&P 500, which has gained roughly 14 percent during the same period.
The players
Moderna
A biotechnology company that develops vaccines and therapeutics and holds a market capitalization of $89.8 billion.
Merck
A pharmaceutical company that collaborated with Moderna on final-stage cancer vaccine clinical trials.
Nasdaq-100
A stock market index composed of 100 of the largest non-financial companies, tracked by over 200 funds.
Martin Shkreli
An investor who has publicly projected that the current Moderna stock bubble will burst within six months.
SanDisk
A technology company whose share price increased 566 percent in 2026, supported by demand for memory chips in AI data centers.
The details
Moderna's stock trajectory was propelled by investor sentiment regarding a successful final-stage cancer vaccine trial announced on August 19, 2026. The stock experienced extreme volatility following that announcement, jumping 177 percent in one day before falling 24 percent the following morning. Since rejoining the Nasdaq-100, the stock has been buoyed by mandatory purchasing from investment funds that track the index's performance.
Timeline
2025: Moderna cut more than 800 jobs.
June 2026: Moderna stock was up 125 percent.
August 19, 2026: Cancer vaccine trial passed the final stage.
October 9, 2026: Moderna shares closed at $225.
October 24, 2026: Full cancer vaccine trial results are expected.
Money Landscape
The stock's recovery follows the 2025 Moderna corporate restructuring that saw the firm cut over 800 jobs. This current performance marks a significant shift from the company's previous period of contraction.
Investors should recognize that fund-driven buying linked to index inclusion can create temporary demand bubbles that may not reflect long-term clinical trial success. Discuss the risks of concentrated positions in volatile biotech stocks with a qualified financial professional.
The takeaway
Market volatility is often amplified when positive news about specific company products collides with forced purchasing from automated index funds. Monitor trial result disclosures and consult with a qualified financial professional before adjusting your exposure to individual biotechnology equities.
What happens next
Full results for the Moderna and Merck cancer vaccine trial are scheduled for release on October 24, 2026, while a national vaccine initiative is projected to launch in December 2026.
Further reading
For broader trends on index rebalancing and sector volatility, review our guide on Stock Markets.
Source note: This article includes information reported by BeInCrypto.
Live Poll
Is now a good time to invest in companies experiencing major stock price volatility?
